Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial - Wikidata - wikimedia - TriplyDB

Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial

Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial

http://www.wikidata.org/entity/Q36981247

about

Cardiac cachexia: hic et nunc Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials)Pharmacology of manipulating lean body mass Cachexia and pancreatic cancer: are there treatment options?Gaps in nutritional research among older adults with cancer Mechanisms of metabolic dysfunction in cancer-associated cachexia Skeletal muscle homeostasis and plasticity in youth and ageing: impact of nutrition and exercise Importance of Breast Cancer Subtype in the Development of Androgen Receptor Directed Therapy.Are we closer to having drugs to treat muscle wasting disease?Therapies for musculoskeletal disease: can we treat two birds with one stone?Sarcopenia, cachexia and aging: diagnosis, mechanisms and therapeutic options - a mini-review.Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signaling Enobosarm (GTx-024, S-22): a potential treatment for cachexia.Sex steroid actions in male bone Estrogens and Androgens in Skeletal Physiology and Pathophysiology.Development of selective androgen receptor modulators (SARMs).Identifying nutritional, functional, and quality of life correlates with male hypogonadism in advanced cancer patients PHARMACOLOGICAL INTERVENTIONS IN FRAILTY AND SARCOPENIA: REPORT BY THE INTERNATIONAL CONFERENCE ON FRAILTY AND SARCOPENIA RESEARCH TASK FORCE.Unlocking the wasting enigma: Highlights from the 8th Cachexia Conference.Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer.Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial).Highlights from the 7th Cachexia Conference: muscle wasting pathophysiological detection and novel treatment strategies.Androgen effects on skeletal muscle: implications for the development and management of frailty.Selective androgen receptor modulators for the treatment of late onset male hypogonadism.Cancer cachexia syndrome: pathogenesis, diagnosis, and new therapeutic options.Integrated therapies for osteoporosis and sarcopenia: from signaling pathways to clinical trials.Targeting the androgen receptor in breast cancer.Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC.Pharmacologic Options for the Treatment of Sarcopenia.The wasting continuum in heart failure: from sarcopenia to cachexia.Advances in pharmacologic strategies for cancer cachexia.Comparative safety evaluation of selective androgen receptor modulators and anabolic androgenic steroids.Cancer-induced muscle wasting: latest findings in prevention and treatment.Bone Pain and Muscle Weakness in Cancer Patients.Rationale for Strengthening Muscle to Prevent Falls and Fractures: A Review of the Evidence.Safety, pharmacokinetics and pharmacological effects of the selective androgen receptor modulator, GSK2881078, in healthy men and postmenopausal women.Mitochondria: Inadvertent targets in chemotherapy-induced skeletal muscle toxicity and wasting?Novel therapeutic options for cachexia and sarcopenia.Evidence for partial pharmaceutical reversal of the cancer anorexia-cachexia syndrome: the case of anamorelin.Update on Management of Cancer-Related Cachexia.

P2860

Q26744140-F91633C0-F014-4606-85E2-C4AE31846C04 Q26747940-959E925A-CD38-465F-9196-E9C820DAC1AA Q26824503-AD9F23B7-C164-4794-9E88-903B7EEF73BC Q27026558-9EB4467C-515F-46BD-AED9-D8BE2FF93709 Q28067552-E99E2CC4-B9AF-40F9-8920-8F2F4F7B2B3E Q28079213-63C38C75-DF1C-4B6F-9D63-567A4B0E1473 Q28262423-AEAE0865-9C5A-486D-A44E-2771283D2958 Q33632582-D90D9400-C32D-48EE-AF23-592A60D818C5 Q33741103-81562F36-6227-4277-A27B-A66D8B0AB7B2 Q33851441-59BCD8D2-8448-45BE-9F99-5283CD37728F Q33956866-F9ADA25D-2CC6-4D4B-882C-1F6CBAE0E4F7 Q33966915-B8CB2010-A6B9-4FCC-8651-B65A7D5F5781 Q34401825-C7F6CF33-09BD-49F7-BD27-D756F6E5B86B Q34437537-B311F69D-3756-4CBE-8F79-F9CA4C1E901D Q34543980-570E21DC-F905-4865-A636-13AB53FD93AA Q34558010-FC3F3929-F68B-47C5-B43D-F907187F513D Q35981188-69CC95F4-1330-4DA8-A264-00D6C3AC3B97 Q36040742-73C51561-2FE2-4912-852B-4D3C2E7AE5A0 Q36706618-0530FBA6-FCFE-464B-8C9A-6E4E03B8B96A Q36908403-4E272736-FD67-4CBC-8500-F8D190D5B7F4 Q37057905-A395DA31-F625-40AA-B328-6B8E31EAE15B Q37635897-0CB7E64F-DF8E-4E46-A3A0-611CBF41118B Q37639192-DE14772F-A60A-496D-9A98-A04B43876322 Q37639204-7854B981-F29D-447B-A7CA-8CAACED0D310 Q38290238-153370FA-A755-4122-9D29-279F5FC1C6EE Q38336740-5E9FDF74-E93D-4000-98B3-8A2D3DDF3486 Q38349376-2F87E396-C0F7-4BCF-AC23-03B5026F7D18 Q38462047-281AFD46-7D57-4AF0-86DD-599CBCF6C620 Q38534875-66B3370A-BA0A-45ED-A9D9-8C00C8D1396B Q38564746-AB8F29D9-6B27-4B3A-8D25-6C4B8F5B0A8E Q38578582-F40AB34D-B838-4B60-B793-7EEEDB2CCE8E Q38592105-CD10F8B5-C45E-406B-A8B3-4067C9395A7C Q38681113-55642908-7CDD-4BBC-98BA-ECD4F70126BC Q38684768-C9CA4860-A041-45A0-ADE7-3A40F42F346F Q38723625-C4FDAF4E-839E-4B8C-8B07-5220A462392B Q38816601-E65E2401-6BA1-4515-B97C-54C64F027826 Q38831900-C754FBF4-4D4E-4C40-88DD-BCD2D5718E32 Q38887581-EBB6481B-694A-4AC1-8D89-7BB57BBD7707 Q38931233-56DB879E-233F-4C43-B960-F84CC0318C37 Q38990581-784D9B10-1CFD-4836-AE75-1415A72E99D3

P2860

Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial

http://www.wikidata.org/entity/Q36981247

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Effects of enobosarm on muscle ...... mised controlled phase 2 trial

@en

type

label

Effects of enobosarm on muscle ...... mised controlled phase 2 trial

@en

prefLabel

Effects of enobosarm on muscle ...... mised controlled phase 2 trial

@en

P1433

Q36981247-D945C147-37AE-4CB4-BC50-C8136262AA1E

P1476

Q36981247-41EEA896-3D7F-4041-852C-6117F6FBAD1B

P2093

Q36981247-3F383AF7-517E-45DB-B428-0260FEEBC419

Q36981247-4730D4A5-117E-4BFF-91D9-57C190626848

Q36981247-5439F893-B3FC-4183-8A1D-658CF27A78EF

Q36981247-7791167E-13F0-4CDD-9BD8-AE5CE35A38B1

Q36981247-A1D72538-4C83-4928-AF82-8B6BFF8B2673

Q36981247-A497A42E-5454-4E82-8CDB-B03EF8C8CAAD

Q36981247-C2F00588-60EE-4B37-8BB2-D070B35E0B53

P2860

Q36981247-0089EC5D-F9B0-407C-9223-16F0F7902DDE

Q36981247-0B7D546B-4BD8-4353-AC8E-C5CFD71285FE

Q36981247-0ECAB1A2-4B58-48F7-959E-E9B6CAF5FB83

Q36981247-16F823EC-3444-455F-9270-289D4F533D5A

Q36981247-2EA93CA5-45B2-47AF-9062-90BD1EF27B3A

Q36981247-3303A3D4-6974-4A4F-AD37-DC856A926081

Q36981247-407AD2B0-C0DB-4044-89D1-C0643C89227E

Q36981247-430B204E-F649-44C4-9C1D-5B03AF06D273

Q36981247-50DA736F-E2C7-4EF3-A7C8-1AB0A0562046

Q36981247-531DCE4F-FBA2-4363-9CEC-46CF448AC935

P304

Q36981247-BEEC59B5-E010-4D2B-A2B3-1EBC17DD8F28

P31

Q36981247-11F59D7F-8082-4ACF-8A12-59B6F5202696

P356

Q36981247-17F27D96-C224-4800-A0AE-88589061F66E

P433

Q36981247-AABE3EED-35EA-4E94-8DAB-707A33A37196

P478

Q36981247-CE58788A-440F-4A2D-A70C-66FC1775D8D1

P50

Q36981247-3DA47FEF-25BE-42A2-8017-9263D38014D8

P577

Q36981247-D7E77573-49E6-4B98-BBCD-7DCA739E542E

P698

Q36981247-F30FA61D-C2C7-4729-B897-4324636D3AC0

P921

Q36981247-E7CF2790-F114-493B-AE82-78EF2C6804AD

P932

Q36981247-58EE3FFF-5B46-46EF-B6AE-B6979D282502

P356

S1470-2045(13)70055-X

P1433

The Lancet Oncology

P1476

Effects of enobosarm on muscle ...... mised controlled phase 2 trial

@en

P2093

Adrian S Dobs

http://www.w3.org/2001/XMLSchema#string

Christopher C Croot

http://www.w3.org/2001/XMLSchema#string

Mary A Johnston

http://www.w3.org/2001/XMLSchema#string

Michael L Hancock

http://www.w3.org/2001/XMLSchema#string

Mitchell S Steiner

http://www.w3.org/2001/XMLSchema#string

Nashat Y Gabrail

http://www.w3.org/2001/XMLSchema#string

Ralph V Boccia

http://www.w3.org/2001/XMLSchema#string

P2860

Body composition and quality of life in adults treated with GH therapy: a systematic review and meta-analysis

Early palliative care for patients with metastatic non-small-cell lung cancer

Clinical review 138: Anabolic-androgenic steroid therapy in the treatment of chronic diseases.

Estimation of Cachexia among Cancer Patients Based on Four Definitions.

The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial.

ABC of palliative care. Anorexia, cachexia, and nutrition.

Definition and classification of cancer cachexia: an international consensus.

Physical performance measures in the clinical setting.

Clinical assessment of body hair growth in women.

Determinants of the sit-to-stand movement: a review.

P304

335-345

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1470-2045(13)70055-X

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-03-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23499390

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

4898053

http://www.w3.org/2001/XMLSchema#string